|Number of pages||1|
|Journal||Frontiers in Oncology|
|Early online date||23 Nov 2022|
|Publication status||Published - 23 Nov 2022|
Bibliographical noteCopyright © 2022 Pinton, Wang, Balzano, Missaglia, Tavian, Boldorini, Fennell, Griffin and Moro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
In the original article, there was an error in the Funding statement as published. The correct funding statement is “The authors acknowledge the financial support of project HERMES (HEreditary Risk in MESothelioma) and Università del Piemonte Orientale (Bando ricerca locale 2019)”.
- malignant pleural mesothelioma
- EZH2 inhibitor
- multicellular spheroids